Lake Street analyst Chad Messer maintained a Buy rating on Bolt Biotherapeutics today and set a price target of $75.00. The company’s shares closed yesterday at $5.66.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Messer is an analyst with an average return of -1.0% and a 38.93% success rate. Messer covers the Healthcare sector, focusing on stocks such as Lantern Pharma, Coya Therapeutics, Inc., and Oncolytics Biotech.
Bolt Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $40.50.
BOLT market cap is currently $10.86M and has a P/E ratio of -0.21.
Read More on BOLT:
Disclaimer & DisclosureReport an Issue
- Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study
- Bolt Biotherapeutics Reports Reduced Losses and Revenue Growth
- Cautious Hold Rating on Bolt Biotherapeutics Amid Uncertain Trial Outcomes and Financial Sustainability
- Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
- Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Blackrock%20Inc_%20logo%20on%20building-%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Semiconductor%20chip%20by%20Mykola%20Pokhodzhay%20via%20iStock.jpg)